0 IAS 2019: highlights and headlines
Find out more about the headlines from the 10th International AIDS Society Conference on HIV Science (IAS 2019) in our round-up of conference news.
Browsing: Basic > Drug Development
0 Infographic: Gonorrhea – a timeline of resistance and it’s mechanisms
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
0 Modulating arbovirus infection via mosquito saliva – an interview with Daniella Lefteri
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.
0 The future of long-acting formulations for HIV – an interview with Jose Arribas
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.
0 Funding received for first Phase III trial of a chikungunya vaccine: June’s industry headlines
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new funding for chikungunya vaccine clinical…
0 ASM Microbe: Cannabidiol found to be active against Gram-positive bacteria
An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
0 The ASPECT-NP study, rationale, results and repercussions – an interview with Igancio Martin-Loeches and Marin Kollef
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
0 FDA rejects Nabriva’s antibiotic Contepo for complicated UTIs: May’s industry headlines
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
0 A peek behind the paper – Nuno Cerca on combating bacterial vaginosis
Take a look behind the scenes of a recent Future Microbiology review, entitled ‘Could targeting neighboring bacterial populations help to combat bacterial vaginosis?’, as we ask the authors about the challenges in treating bacterial vaginosis (BV) and the future of this field.
0 Laser-induced vapor nanobubbles: a new local hotspot in the anti-biofilm landscape?
Based on the demonstrated potential of laser-induced vapor nanobubbles to treat bacterial biofilm infections, we provide recommendations for future work in order to further mature this new technology into a promising anti-biofilm approach.
